SCHEDULE: Affinity Asset Advisors Discloses 9.1% Stake in Ovid Therapeutics

Affinity Asset Advisors, LLC and Michael Cho have reported beneficial ownership of 15,635,484 shares, representing 9.1% of Ovid Therapeutics Inc.'s common stock, as of March 31, 2026.

Summary

• Affinity Asset Advisors, LLC and Michael Cho (collectively, the "Reporting Persons") have filed a Schedule 13G, indicating their beneficial ownership of Ovid Therapeutics Inc. common stock.
• As of March 31, 2026, the Reporting Persons beneficially own 15,635,484 shares of common stock.
• This ownership stake represents approximately 9.1% of the outstanding common stock.
• The reported shares include 4,999,166 shares issuable upon the exercise of warrants held by Affinity Healthcare Fund, LP, for which Affinity Asset Advisors, LLC serves as the investment manager.
• Affinity Asset Advisors, LLC has sole voting and dispositive power over these shares, and Michael Cho, as the managing member of the Adviser, may be deemed a beneficial owner.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. It reports on an existing ownership stake and does not contain new financial performance data or strategic announcements from the company itself.

Positives

• Significant ownership stake of 9.1% in Ovid Therapeutics Inc. by Affinity Asset Advisors and Michael Cho.
• The ownership includes exercisable warrants, indicating a potential for increased stake.
• The filing is made under Rule 13d-1(b), suggesting the securities were acquired and are held in the ordinary course of business and not for the purpose of influencing control.

Risks

• The filing does not detail specific risks associated with Ovid Therapeutics Inc. itself, but rather reports on ownership.
• Potential for future changes in ownership percentage based on warrant exercise or market activity.

Future Outlook

The filing does not contain forward-looking statements or guidance from Ovid Therapeutics Inc. It solely reports on the ownership stake of Affinity Asset Advisors and Michael Cho.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors and significant individual investors accumulating substantial stakes in publicly traded companies. This filing indicates a notable investment by Affinity Asset Advisors in Ovid Therapeutics, a biotechnology company, which is typical for investment managers in this sector.

Stakeholder Impact

• Shareholders: The filing provides transparency regarding a significant ownership block, which may influence market perception and trading activity.
• Management of Ovid Therapeutics Inc.: Awareness of substantial beneficial ownership by external parties.
• Potential Investors: The filing may signal investor confidence or interest in Ovid Therapeutics Inc.

Next Steps

• Affinity Asset Advisors and Michael Cho will continue to hold their shares in Ovid Therapeutics Inc.
• Future filings may be required if their ownership stake changes significantly.

Key Dates

Keywords

Schedule 13G, Ovid Therapeutics Inc., Affinity Asset Advisors, Michael Cho, Beneficial Ownership, Common Stock, Warrants, SEC Filing, Investment Management